Marker Therapeutics Inc (MRKR)

[pharmeng]

From FierceBiotech

AZ and VentiRx team up for PDL1-oncology vax trial in ovarian cancer

Ovarian cancer has few treatments and suffers from poor diagnosis, although AZ already markets Lynparza, an ADP-ribose polymerase (PARP) inhibitor, that's licensed for ovarian cancer patients who have BRCA gene mutations identified through a genetic test. This combo trial is seeking to expand on this and treat more women who do not have the BRCA gene.

There are currently a number of pharma and biotechs also researching this area, including GamaMabs' immune-activating cancer candidate and Clovis Oncology's ($CLVS) rucaparib.